Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (41-50 of 404) with videos related to

Pageof 41
Sort By:
Neuro-Oncology|October 31, 2015
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapyDavid A Reardon, Mark R Gilbert, Wolfgang Wick, et al.
Expert Opinion on Investigational Drugs|July 12, 2008
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiformeDavid A Reardon, L Burt Nabors, Roger Stupp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2020
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?Mustafa Khasraw, David A Reardon, Michael Weller, et al.
Current Treatment Options in Neurology|April 5, 2013
Treatment options in newly diagnosed glioblastomaEudocia Q Lee, Lakshmi Nayak, Patrick Y Wen, et al.
Current Treatment Options in Oncology|February 8, 2008
The emerging role of anti-angiogenic therapy for malignant gliomaDavid A Reardon, Annick Desjardins, Jeremy N Rich, et al.
The Journal of Molecular Diagnostics : JMD|September 18, 2016
The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCRDaniel Xia, David A Reardon, Jacqueline L Bruce, et al.
Expert Review of Neurotherapeutics|March 28, 2012
A novel treatment for glioblastoma: integrin inhibitionMarc C Chamberlain, Timothy Cloughsey, David A Reardon, et al.
Neurology|July 14, 2004
Kluver-Bucy syndrome related to gliomaMichael A Badruddoja, James Vredenburgh, Terry S Peery, et al.
Neuro-Oncology|September 12, 2008
Experience with irinotecan for the treatment of malignant gliomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.
Neuro-Oncology|November 23, 2023
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?Ethan Chen, Alexander L Ling, David A Reardon, et al.
Pageof 41

Showing results (41-50 of 404) with videos related to

Sort By:
Pageof 41
Neuro-Oncology|October 31, 2015
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapyDavid A Reardon, Mark R Gilbert, Wolfgang Wick, et al.
Expert Opinion on Investigational Drugs|July 12, 2008
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiformeDavid A Reardon, L Burt Nabors, Roger Stupp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2020
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?Mustafa Khasraw, David A Reardon, Michael Weller, et al.
Current Treatment Options in Neurology|April 5, 2013
Treatment options in newly diagnosed glioblastomaEudocia Q Lee, Lakshmi Nayak, Patrick Y Wen, et al.
Current Treatment Options in Oncology|February 8, 2008
The emerging role of anti-angiogenic therapy for malignant gliomaDavid A Reardon, Annick Desjardins, Jeremy N Rich, et al.
The Journal of Molecular Diagnostics : JMD|September 18, 2016
The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCRDaniel Xia, David A Reardon, Jacqueline L Bruce, et al.
Expert Review of Neurotherapeutics|March 28, 2012
A novel treatment for glioblastoma: integrin inhibitionMarc C Chamberlain, Timothy Cloughsey, David A Reardon, et al.
Neurology|July 14, 2004
Kluver-Bucy syndrome related to gliomaMichael A Badruddoja, James Vredenburgh, Terry S Peery, et al.
Neuro-Oncology|September 12, 2008
Experience with irinotecan for the treatment of malignant gliomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.
Neuro-Oncology|November 23, 2023
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?Ethan Chen, Alexander L Ling, David A Reardon, et al.
Pageof 41